FDA Reports Limited Availability Of Mounjaro Injections (10 mg/.5 ml, 7.5 mg/.5 ml, 15 mg/.5 ml) Through Q2 2024 - Website
Portfolio Pulse from Benzinga Newsdesk
The FDA has reported limited availability of Mounjaro injections (10 mg/.5 ml, 7.5 mg/.5 ml, 15 mg/.5 ml) through Q2 2024.
June 04, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly, the manufacturer of Mounjaro, may face short-term supply constraints due to the FDA's report of limited availability of the drug through Q2 2024.
The limited availability of Mounjaro injections could impact Eli Lilly's sales and revenue in the short term, leading to potential negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novo Nordisk, a competitor in the diabetes and obesity treatment market, might benefit from Eli Lilly's supply constraints of Mounjaro.
As a competitor, Novo Nordisk might capture market share from Eli Lilly if Mounjaro's limited availability affects patient access.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50